Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma

Sponsor
Henan Cancer Hospital
Study ID
NCT03383237
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to confirm the safety and efficacy of Apatinib as the Second-line Therapy in Malignant Melanoma.

Key Dates

First listed
Dec 26, 2017
Start date
Nov 29, 2017
Status verified
Nov 2017
Primary completion
Nov 30, 2018
Completion
Nov 30, 2019

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib
    Apatinib 500mg/d,q.d.,p.o.

Primary Outcome Measure

Progression-free Survival (PFS) [ Time Frame: up to 2 year ]

Central Contacts

Related Studies